ECM
EGRX

Everence Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Everence Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,970
Closed -$221K – 751
2022
Q2 		$221K Buy
+4,970
New +$228K 0.02% 608

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Everence Capital Management's EGRX Position: Q3 2022 in Review

Everence Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 4,970 shares — an estimated $221K sold.

Everence Capital Management first reported a position in EGRX in Q2 2022 and held it in 1 quarter. The position peaked at $221K in Q2 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • Everence Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Everence Capital Management sold 4,970 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $221K.
  • Everence Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2022 and held it in 1 quarter.
  • Everence Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $221K in Q2 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Everence Capital Management's 13F filing for Q3 2022, filed 7 Oct 2022.